Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ruconest for IVIG-related ADRs
NCT03576469Phase 4Completed
- Sponsor
- IMMUNOe Health and Research Centers
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 4 trial of c1-esterase inhibitor in adverse drug reaction (ADR), sponsored by IMMUNOe Health and Research Centers. Started Jun 2018; status: completed.
02
Drugs
c1-esterase inhibitor
03
Conditions
adverse drug reaction (ADR)
Beyond the preview
Go deeper on NCT03576469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576469.